Podcast Episode
Episode 30: Update on Axitinib plus Pembrolizumab in Renal Cancer (KEYNOTE 426)
About this episode
Betsy Plimack discusses the updated data with a minimum of 23 months' follow up. Dr. Brian Rini and Professor Tom Powles asks what it adds.